Special Issue "Extracellular Vesicles: Biology and Potentials in Cancer Therapeutics"
Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 52919
A printed edition of this Special Issue is available here.
Interests: cancer biomarker; evidence-based medicine; extracellular vesicles; genomics; microRNA; molecular diagnostics; non-coding RNAs; nasopharyngeal carcinoma; next-generation sequencing; non-small cell lung cancer; proteomics; drug repurposing and bioinformatics
Special Issues, Collections and Topics in MDPI journals
Special Issue in International Journal of Molecular Sciences: Molecular Classification of Human Cancer: Diagnosis and Treatment
Special Issue in International Journal of Molecular Sciences: Liquid Biopsy for Clinical Application
Special Issue in International Journal of Molecular Sciences: Big Data for Oncology
Special Issue in International Journal of Molecular Sciences: Next-Generation Sequencing for Clinical Application
Special Issue in International Journal of Molecular Sciences: Molecular Classification of Human Cancer: Diagnosis and Treatment 2016
Special Issue in International Journal of Molecular Sciences: Chimeric Antigen Receptor (CAR) T Cell Therapy
Special Issue in International Journal of Molecular Sciences: Precision Medicine—From Bench to Bedside
Special Issue in Cancers: The Microbiome-Immunity-Cancer Axis in Cancers
Special Issue in International Journal of Molecular Sciences: Extracellular Vesicles: Biology and Potentials in Cancer Therapeutics 2.0
Special Issue in Biomolecules: Drug Repurposing in Cancer Therapies
In contrast to the artificial vehicles for drug delivery in cancer, extracellular vesicle (EV) as intercellular communication has attracted tremendous interest from the scientific community for use as a vehicle for therapeutics. EVs have been studied as delivery vehicles to transport drugs, proteins, and non-coding RNA for therapeutic purposes. Various approaches are emerging, with interesting experimental results.
The efficiency and specificity of drug delivery should be considered for targeting specific cell populations in dealing with tumor heterogeneity. EVs can be engineered to deliver specific bioactive molecules to target cells. The exploitation of their molecular composition and physical properties, as well as the use of bio-techniques to modify their content, are important issues to target them to specific cells/tissues/organs.
This Special Issue particularly focuses on how EVs offer a solution to molecular cancer therapeutics, thereby providing an efficient and effective way to treat cancer that marks a paradigm shift in modern oncology.
Original papers and review articles that focus on the latest advances of EVs are welcome. Papers and review articles on but not restricted to the following key areas will be covered:
- Biology of EVs from various sources, e.g., platelet EVs, autologous cancer cell-derived EVs, etc.;
- Red blood cell EVs as RNA-based therapeutics;
- Mesenchymal stem cell-derived EVs as therapeutics and drug delivery platforms;
- Macrophage-derived exosome–mimetic hybrid vesicles for targeted drug delivery in cancer;
- Strategies in drug delivery by EVs, e.g., the modification of EV membranes;
- Cancer EVs and their association with the microenvironment, including cancer-associated fibroblasts;
- Clinical requirements for EV as a vehicle for cancer therapeutics;
- EV-based therapeutics: natural versus engineered targeting;
- EV-based therapeutics: safety and toxicity.
Dr. William Cho
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- extracellular vesicle
- precision oncology
- cancer biomarker
- non-coding RNA
- molecular diagnostics